Avid Bioservices Inc (CDMO)

[entdoc]

DO THE MATH Simple, really. We know what SOC average overal survival is in MANY thousands of patients. No question that average survival with NSCLC is about 7.2mo. Bavi and SOC are mixed in three treatment groups...possibly randomly. The PII Bavi trial has become a multi-dose asynchronously delivered Bavi + SOC. Did the SOC group + placebo follow the usual course, or did that group show abnormal survival, indicating that the dread Bavi seeped into the control group as well. Mathematically, it seems correct. The question therefore devolves to whether the overall group showed significant improved survival. I think we lucked out. The next logical move by FDA would be to split the difference between 1mg and 3mg....Launch at 2mg, and study 1mg and 3mg if it comes to that. Let's keep the ball moving. You got a glimpse of the big leagues. Gonna get sent packing? the big leagues. "Noisers" is a new term, and Noisemakers are louder here than ever. Deeply imbedded double agents. Big dollars. Experienced actors. All the elements...